Search
+
    SEARCHED FOR:

    TITAN Q1 UPDATE IMPACT

    HDFC Bank shares fall 4% as Q1 update disappoints investors

    HDFC Bank shares, previously rising due to potential MSCI weightage increase, fell over 4% on Friday to Rs 1,665.55 on BSE. This decline followed a sharp drop in CASA ratio in its June quarter update. Deposit growth was soft at 15.3% YoY (pro-forma), flat sequentially, with CASA declining 5% QoQ, lowering CASA ratio by 190 bps to 36%

    HDFC Bank gross advances jump 52.6% on-year in Q1 to Rs 24.8 lakh crore

    HDFC Bank's gross advances increased by 52.6% year-on-year to ₹24.87 lakh crore in the quarter ending June 30, driven by its merger with HDFC Limited last July. Excluding the merger impact, advances grew by 14.9% from June 30, 2023, reaching ₹25.08 lakh crore by March 31, 2024.

    HDFC Bank Q1 Update: Advances soar 53% YoY to Rs 24.87 lakh cr; deposits jump 24%

    Excluding the impact of the HDFC merger with the bank on July 1, 2023, the bank's gross advances grew by 15% compared to the same period last year. During the first quarter, retail loans increased by approximately Rs 18,600 crore, and commercial and rural banking loans grew by around Rs 7,200 crore. However, corporate and other wholesale loans decreased by Rs 26,600 crore compared to the preceding March quarter.

    Could IT make a meaningful comeback in Q1? Deven Choksey explains

    Deven Choksey highlights the importance of sticking with larger banks for business growth and emphasizes the positive outlook for IT companies. Additionally, L&T's promising future is underlined by margin expansion and improved execution. Choksey further says that one shouldn't expect too big a rally in IT and that one should stay focused on some of the larger banks as far as the portfolio investment is concerned

    OPEC sticks to 2024 oil demand growth forecast, but trims Q1 view

    The Organization of the Petroleum Exporting Countries, in a monthly report, said world oil demand will rise by 2.25 million barrels per day (bpd) in 2024 and by 1.85 million bpd in 2025. Both forecasts were unchanged from last month.

    Glenmark Pharma Q4 Results: Net loss widens to Rs 121 crore YoY

    Glenmark Pharma Q4 Results: The rise in loss was on account of declining sales in the US and exceptional items. It had reported a net loss of Rs 34.5 crore in the corresponding quarter of the previous year. In FY24, Glenmark's consolidated revenue reached Rs. 11,813 crore, a 2% increase year-over-year. The company's EBITDA margin for the fiscal year was 10.1%, primarily due to a one-time impact on sales in the India business during the third quarter.

    The Economic Times
    BACK TO TOP